Media headlines about Shire (NASDAQ:SHPG) have trended somewhat positive on Friday, according to Accern Sentiment Analysis. The research group rates the sentiment of media coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Shire earned a news impact score of 0.08 on Accern’s scale. Accern also gave news headlines about the biopharmaceutical company an impact score of 45.6595451492786 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
These are some of the headlines that may have effected Accern Sentiment Analysis’s scoring:
- Sarah Coles is council’s new business support officer (parkeschampionpost.com.au)
- Council divided on controversial proposal (gleninnesexaminer.com.au)
- Shire City Herbals Completes $1.4 Million Expansion Project (iberkshires.com)
- Amazon’s New Lord of the Rings TV Series – What We Know, and What We Hope For (prweb.com)
- Hills Shire Councillors order by-election after Raymond Harty resignation (dailytelegraph.com.au)
SHPG has been the subject of several analyst reports. Royal Bank of Canada set a $192.00 target price on Shire and gave the stock a “buy” rating in a research note on Monday, February 5th. Cantor Fitzgerald set a $222.00 target price on Shire and gave the stock a “buy” rating in a research note on Wednesday, March 28th. B. Riley lowered their target price on Shire from $201.00 to $181.00 and set a “buy” rating for the company in a research note on Friday, February 16th. ValuEngine cut Shire from a “hold” rating to a “sell” rating in a research note on Wednesday, May 2nd. Finally, Zacks Investment Research raised Shire from a “sell” rating to a “hold” rating in a research note on Friday, March 23rd. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating and twelve have given a buy rating to the company. Shire presently has an average rating of “Buy” and a consensus target price of $201.64.
Shire (NASDAQ:SHPG) last announced its quarterly earnings results on Thursday, April 26th. The biopharmaceutical company reported $3.86 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $3.58 by $0.28. The company had revenue of $3.77 billion during the quarter. Shire had a return on equity of 13.60% and a net margin of 28.96%. The firm’s quarterly revenue was up 5.4% on a year-over-year basis. During the same period last year, the firm earned $3.63 earnings per share. equities research analysts expect that Shire will post 15.26 earnings per share for the current year.
Shire Company Profile
Shire plc, a biotechnology company, researches, develops, licenses, manufactures, markets, distributes, and sells medicines for rare diseases and other specialized conditions worldwide. The company offers products in therapeutic areas, including hematology, genetic diseases, neuroscience, immunology, internal medicine, ophthalmology, and oncology.
Receive News & Ratings for Shire Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire and related companies with MarketBeat.com's FREE daily email newsletter.